A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line

Inclusion Criteria: * Aged 18 years or older at the time of providing written informed consent * Diagnosis of malignancy that requires placement of a PICC within the next 3 weeks for administration of chemotherapy (PICC anticipated to be required for at least 1 month) * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 \[Oken et al, 1982\], and investigator's expectation that performance status will remain 0, 1, or 2 for the duration of the study Exclusion Criteria: * Active bleeding or with a current clinically significant coagulopathy (eg, international normalized ratio \[INR\] \> 1.5) or clinically significant risk for bleeding (eg, recent intracranial hemorrhage or bleeding peptic ulcer within the last 4 weeks) * History of venous thrombosis, myocardial infarction or cerebrovascular event within 3 months, or a prothrombotic disorder (eg, antithrombin III, protein C or S deficiency) * Life expectancy less than study duration (110 days) * Platelet count of \< 20 × 109/L on the day of dose 1 (Day 1) or within 7 days before first dosing * Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m2 * Treatment with antiplatelet or anticoagulant medication, including thrombosis prophylaxis, within 10 days prior to insertion of the PICC * Chemotherapy regimen that would be expected to drop the platelet count to \< 20 × 109/L * Chemotherapy regimen with heparin mixed into IV bags (eg, dalteparin 2500 IU/day) * Difficult IV access that would preven…